The final 3 year data from the landmark
Symplicity HTN-1 study was published in the Lancet on the 7th of November, authored by the head of CCRETherapeutics, Prof Henry Krum.
Symplicity HTN-1 was the first proof of
principle demonstration of the beneficial blood pressure-lowering effect of a
new technique called percutaneous renal sympathetic denervation. Prof Krum is
Principal Investigator of that global study effort. This is a minimally
invasive approach to damage the nerves that surround the main artery to the
kidneys which provide signals to the kidneys (and brain) to drive blood
pressure up.
The 3 year data shows that reductions in 30 mmHg of systolic blood pressure (the "top reading") were sustained out to this time utilising this procedure. There were minimal major short- or long-term safety issues with the procedure. These initial data together with subsequent research has established renal denervation as a viable option in the treatment of patients whose blood pressure remains "resistant" to drug and other standard treatments.
The 3 year data shows that reductions in 30 mmHg of systolic blood pressure (the "top reading") were sustained out to this time utilising this procedure. There were minimal major short- or long-term safety issues with the procedure. These initial data together with subsequent research has established renal denervation as a viable option in the treatment of patients whose blood pressure remains "resistant" to drug and other standard treatments.
No comments:
Post a Comment